Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm's fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET.
2024年8月26日加州南旧金山（GLOBE NEWSWIRE）-- 标准生物工具公司（Nasdaq:LAB）今天宣布，其总裁兼首席执行官Michael Egholm博士将在即将于9月4日（星期三）至9月6日（星期五）在纽约市举行的摩根士丹利第22届全球医疗保健大会上发表演讲。Egholm博士的炉边谈话将于2024年9月6日星期五上午8:30举行。
The presentation will be webcast live and available on the Investor Relations page of the Company's website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
演示将通过网络直播，并可在公司网站的投资者关系页面的活动与演示上观看。网络直播的录像将被存档，并可在标准生物工具投资者关系页面investors.standardbio.com上观看。
About Standard BioTools Inc.
关于标准生物工具股份有限公司。
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook, LinkedIn, and YouTube.
Standard BioTools Inc.（纳斯达克：LAB）是SomaLogic Inc.的母公司，此前被称为Fluidigm Corporation，拥有一系列基本的、标准化的下一代技术，帮助生物医学研究人员更快、更好地开发药物。作为领先的解决方案提供商，该公司使用其专有的质量细胞术和微流控技术提供可靠和可重复的健康和疾病见解，帮助将科学发现转化为更好的患者成果。Standard BioTools与全球领先的学术界、政府、制药、生物技术、植物和动物研究和临床实验室合作，专注于转化和临床研究中最紧迫的需求，包括肿瘤学、免疫学和免疫疗法。了解更多信息，请访问standardbio.com或在X、Facebook、LinkedIn和YouTube上与我们联系。
For Research Use Only. Not for use in diagnostic procedures.
仅用于研究。不能用于诊断程序。
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. 2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
可能适用有限使用标签许可证和其他条款：standardbio.com/legal/salesterms。专利和许可信息：standardbio.com/legal/notices。
商标：standardbio.com/legal/trademarks。任何其他商标均为其各自所有者的唯一财产。2024年Standard BioTools Inc.（前名Fluidigm Corporation）。保留所有权利。
Investor Contact:
投资者联系：
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
大卫·霍姆斯
吉尔马丁集团有限责任公司
(332) 330-1031
ir@standardbio.com